Presenting on the above topic is Stephen Mahler, Associate Professor, Australian Institute for Bioenginering and Nanotechnology, University of Queensland . He will be speaking at 5th Annual BioPharma Asia Convention 2012, held on 19th to 22nd March 2012 at Marina Bay Sands, Singapore. He will be conducting an on-floor seminar at Theatre 1 at 13:00 on the 21st of March.
Here is a short abstract on what he will be speaking on:
Over the past 10 years Antibodies have revolutionised therapy for the major disease indications such as cancer and inflammatory disorders, including rheumatoid arthritis, Crohns disease and ankylosing spondylitis. More recently antibodies are also finding application in infectious disease, cardiovascular disease and other disease indications. There are over 20 antibodies approved for human administration, with most of these being CDR grafted, and an increasing number in clinical trials that are derived from antibody libraries by phage display, and from transgenic mice by conventional hybridoma technology. There is only one bispecific mAb approved, Catumaxomab (removab), which targets the tumor antigen EpCAM with one arm, and CD3 (T cells) with the other arm. In this way bispecific antibodies are able to mediate effector cell recruitment. However there are other ways in which bispecific antibodies may be harnessed in therapeutic settings, which may offer improved therapies for disease indications. There are a variety of drug delivery vehicles (nanoparticles) that are in various stages of development, capable of carrying drug payloads, which require specific targeting to diseased tissue. Engineered bispecific antibodies could play a key role in the future in realising the potential of these delivery vehicles. There are many ways to construct recombinant bispecific antibodies, including diabodies, dual variable domain antibodies, Fcabs and triabodies for example, which can be expressed in mammalian, yeast or bacterial production systems. Various ways to construct bispecific antibodies will be discussed, including some examples and methodologies for targeting nanoparticles to cancer cells.